Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
10 "So Young Yoon"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer
In Hae Park, Joo Hyuk Sohn, Sung Bae Kim, Keun Seok Lee, Joo Seop Chung, Soo Hyeon Lee, Tae You Kim, Kyung Hae Jung, Eun Kyung Cho, Yang Soo Kim, Hong Suk Song, Jae Hong Seo, Hun Mo Ryoo, Sun Ah Lee, So Young Yoon, Chul Soo Kim, Yong Tai Kim, Si Young Kim, Mi Ryung Jin, Jungsil Ro
Cancer Res Treat. 2017;49(3):569-577.   Published online September 12, 2016
DOI: https://doi.org/10.4143/crt.2016.289
AbstractAbstract PDFPubReaderePub
Purpose
Genexol-PM is a Cremophor EL–free formulation of low-molecular-weight, non-toxic, and biodegradable polymeric micelle-bound paclitaxel. We conducted a phase III study comparing the clinical efficacy and toxicity of Genexol-PM with conventional paclitaxel (Genexol).
Materials and Methods
Patients were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 intravenously every 3 weeks. The primary outcome was the objective response rate (ORR).
Results
The study enrolled 212 patients, of whom 105 were allocated to receive Genexol-PM. The mean received dose intensity of Genexol-PM was 246.8±21.3 mg/m2 (95.0%), and that of Genexol was 168.3±10.6 mg/m2 (96.2%). After a median follow-up of 24.5 months (range, 0.0 to 48.7 months), the ORR of Genexol-PM was 39.1% (95% confidence interval [CI], 31.2 to 46.9) and the ORR of Genexol was 24.3% (95% CI, 17.5 to 31.1) (pnon-inferiority=0.021, psuperiority=0.016). The two groups did not differ significantly in overall survival (28.8 months for Genexol-PM vs. 23.8 months for Genexol; p=0.52) or progression-free survival (8.0 months for Genexol-PM vs. 6.7 months for Genexol; p=0.26). In both groups, the most common toxicities were neutropenia, with 68.6% occurrence in the Genexol-PM group versus 40.2% in the Genexol group (p < 0.01). The incidences of peripheral neuropathy of greater than grade 2 did not differ significantly between study treatments.
Conclusion
Compared with standard paclitaxel, Genexol-PM demonstrated non-inferior and even superior clinical efficacy with a manageable safety profile in patients with metastatic breast cancer.

Citations

Citations to this article as recorded by  
  • Revolutionizing cancer treatment: ROS-induced apoptosis via nanoformulated alkaloids
    Swathi Putta, Santhosh Kumar Chinnaiyan, Ramadevi Korni, Venkata Radha Gadela
    Journal of Drug Delivery Science and Technology.2025; 104: 106556.     CrossRef
  • Administration of Inhibitory Molecules through Nanoparticles in Breast Cancer Therapy
    Christian Rafael Quijia, Andreina Quevedo Enríquez, Carlos Daniel Zappia, Roxana Noemí Peroni, Marlus Chorilli
    Current Medicinal Chemistry.2024; 31(6): 726.     CrossRef
  • Innovative strategies for effective paclitaxel delivery: Recent developments and prospects
    Sławomir Wileński, Agnieszka Koper, Paulina Śledzińska, Marek Bebyn, Krzysztof Koper
    Journal of Oncology Pharmacy Practice.2024; 30(2): 367.     CrossRef
  • Effect of zwitterionic sulfobetaine incorporation on blood behaviours, phagocytosis, and in vivo biodistribution of pH-responsive micelles with positive charges
    Chengwei Wang, Hao Liu, Hu Lin, Rui Zhong, Hao Li, Jiaxin Liu, Xianglin Luo, Meng Tian
    Journal of Materials Chemistry B.2024; 12(6): 1652.     CrossRef
  • Reexamining in vivo fate of paclitaxel-loaded polymeric micelles
    Shiqi Lin, Yifei Yu, Ercan Wu, Tianhao Ding, Yuxiu Chu, Feng Pan, Yang Yang, Changyou Zhan
    Nano Today.2024; 56: 102255.     CrossRef
  • Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials
    Ana Serras, Célia Faustino, Lídia Pinheiro
    Pharmaceutics.2024; 16(8): 1047.     CrossRef
  • Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
    Giuseppe Longobardi, Thomas Lee Moore, Claudia Conte, Francesca Ungaro, Ronit Satchi‐Fainaro, Fabiana Quaglia
    WIREs Nanomedicine and Nanobiotechnology.2024;[Epub]     CrossRef
  • Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer
    Jia-xin Qiao, Dong-yan Guo, Huan Tian, Zhan-peng Wang, Qiang-qiang Fan, Yuan Tian, Jing Sun, Xiao-fei Zhang, Jun-bo Zou, Jiang-xue Cheng, Fei Luan, Bing-tao Zhai
    Materials Today Bio.2024; 29: 101358.     CrossRef
  • Microwave‐Assisted Synthesis of Porous Biomolecule‐Incorporated Metal‐Organic Frameworks as Efficient Nanocarriers for Anti‐Cancer Drugs
    Trang Thi Thu Nguyen, Bao Quang Gia Le, Vy Tran Hanh Nguyen, Jae‐Hyoung Lee, Ngoc Xuan Dat Mai, Linh Ho Thuy Nguyen, Tan Le Hoang Doan
    ChemistrySelect.2023;[Epub]     CrossRef
  • Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemo‐ and radioresistances
    Prithwish Kola, Prasanth Kumar Bhusetty Nagesh, Pritam Kumar Roy, K. Deepak, Rui Luis Reis, Subhas C. Kundu, Mahitosh Mandal
    WIREs Nanomedicine and Nanobiotechnology.2023;[Epub]     CrossRef
  • Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives
    Mangala Hegde, Nikunj Naliyadhara, Jyothsna Unnikrishnan, Mohammed S. Alqahtani, Mohamed Abbas, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
    Cancer Letters.2023; 556: 216066.     CrossRef
  • Influence of lung cancer model characteristics on tumor targeting behavior of nanodrugs
    Weixia Xu, Shengmin Yang, Linwei Lu, Qianzhu Xu, Sunyi Wu, Jianfen Zhou, Jiashen Lu, Xingyan Fan, Nana Meng, Yuan Ding, Xudong Zheng, Weiyue Lu
    Journal of Controlled Release.2023; 354: 538.     CrossRef
  • Metastatic Breast Cancer: Review of Emerging Nanotherapeutics
    Ranga Dissanayake, Rheal Towner, Marya Ahmed
    Cancers.2023; 15(11): 2906.     CrossRef
  • Efficacy and Safety of Nanopaclitaxel Formulation for Cancer Treatment: Evidence From Randomized Clinical Trials
    Xiangmin Deng, Xiaoqin Huang, Xiaoyan Dong, Genxiang Mao, Wenmin Xing
    Nanomedicine.2023; 18(10): 833.     CrossRef
  • Combination Therapy as a Promising Way to Fight Oral Cancer
    João P. N. Silva, Bárbara Pinto, Luís Monteiro, Patrícia M. A. Silva, Hassan Bousbaa
    Pharmaceutics.2023; 15(6): 1653.     CrossRef
  • Nano delivery system for paclitaxel: Recent advances in cancer theranostics
    Na Ying, Sisi Liu, Mengmeng Zhang, Jing Cheng, Linghuan Luo, Jiayi Jiang, Gaofan Shi, Shu Wu, Jun Ji, Haoyuan Su, Hongzhi Pan, Dongdong Zeng
    Colloids and Surfaces B: Biointerfaces.2023; 228: 113419.     CrossRef
  • Current Perspectives on Paclitaxel: Focus on Its Production, Delivery and Combination Therapy
    Yibin Liu, Fenglan Zhao, Qibao Wang, Qingjie Zhao, Guige Hou, Qingguo Meng
    Mini-Reviews in Medicinal Chemistry.2023; 23(18): 1780.     CrossRef
  • Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review
    Sheng Sun, Ye-hui Wang, Xiang Gao, He-yong Wang, Lu Zhang, Na Wang, Chun-mei Li, Shao-quan Xiong
    Frontiers in Bioengineering and Biotechnology.2023;[Epub]     CrossRef
  • Paclitaxel prodrug-encapsulated polypeptide micelles with redox/pH dual responsiveness for cancer chemotherapy
    Jinyu Liu, Yanhao Zhang, Chao Liu, Yuhao Jiang, Zihao Wang, Xinsong Li
    International Journal of Pharmaceutics.2023; 645: 123398.     CrossRef
  • Biodegradable polyester-based nano drug delivery system in cancer chemotherapy: a review of recent progress (2021–2023)
    Zongheng Wang, Miaomiao Xiao, Fangliang Guo, Yue Yan, Hong Tian, Qianshi Zhang, Shuangyi Ren, Liqun Yang
    Frontiers in Bioengineering and Biotechnology.2023;[Epub]     CrossRef
  • Comparison of triblock copolymeric micelles based on α- and ε-poly(L-lysine): a Cornelian choice
    Franck Marquet, Viorica Patrulea, Gerrit Borchard
    Polymer Journal.2022; 54(2): 199.     CrossRef
  • Current understandings and clinical translation of nanomedicines for breast cancer therapy
    Yike Jiang, Ziyi Jiang, Mingzhe Wang, Lan Ma
    Advanced Drug Delivery Reviews.2022; 180: 114034.     CrossRef
  • Poly(ϵ-Caprolactone)-Methoxypolyethylene Glycol (PCL-MPEG)-Based Micelles for Drug-Delivery: The Effect of PCL Chain Length on Blood Components, Phagocytosis, and Biodistribution
    Zemin Hou, Wencheng Zhou, Xi Guo, Rui Zhong, Ao Wang, Jiehua Li, Ying Cen, Chao You, Hong Tan, Meng Tian
    International Journal of Nanomedicine.2022; Volume 17: 1613.     CrossRef
  • Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy
    Prashant Pandey, Dilip Kumar Arya, Mohan Kumar Ramar, Kumarappan Chidambaram, P.S. Rajinikanth
    Drug Discovery Today.2022; 27(9): 2526.     CrossRef
  • Biophysical Characterization of Interactions between Serum Albumin and Block Copolymer Micelles
    Catherine F. Dial, Richard A. Gemeinhart
    ACS Biomaterials Science & Engineering.2022; 8(7): 2899.     CrossRef
  • Micelles in Cancer Therapy: An Update on Preclinical and Clinical Status
    Rabia Aqeel, Nidhi Srivastava, Poonam Kushwaha
    Recent Patents on Nanotechnology.2022; 16(4): 283.     CrossRef
  • Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
    Juanjuan Yang, Xiaojin Wang, Bingshun Wang, Kinam Park, Karen Wooley, Shiyi Zhang
    Advanced Drug Delivery Reviews.2022; 190: 114525.     CrossRef
  • In Vivo Sustained Release of the Retrograde Transport Inhibitor Retro-2.1 Formulated in a Thermosensitive Hydrogel
    Robin Vinck, Laetitia Anvi Nguyen, Mathilde Munier, Lucie Caramelle, Diana Karpman, Julien Barbier, Alain Pruvost, Jean-Christophe Cintrat, Daniel Gillet
    International Journal of Molecular Sciences.2022; 23(23): 14611.     CrossRef
  • Clinical Translation of Self‐Assembled Cancer Nanomedicines
    Peng Mi, Kanjiro Miyata, Kazunori Kataoka, Horacio Cabral
    Advanced Therapeutics.2021;[Epub]     CrossRef
  • From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
    Guillermo Valdivia, Ángela Alonso-Diez, Dolores Pérez-Alenza, Laura Peña
    Frontiers in Veterinary Science.2021;[Epub]     CrossRef
  • Advanced Biotechnologies: Collections of Plant Cell Cultures As a Basis for Development and Production of Medicinal Preparations
    E. V. Popova, A. V. Nosov, M. V. Titova, D. V. Kochkin, A. A. Fomenkov, I. E. Kulichenko, A. M. Nosov
    Russian Journal of Plant Physiology.2021; 68(3): 385.     CrossRef
  • Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation
    Xin Luan, Hebao Yuan, Yudong Song, Hongxiang Hu, Bo Wen, Miao He, Huixia Zhang, Yan Li, Feng Li, Pan Shu, Joseph P. Burnett, Nathan Truchan, Maria Palmisano, Manjunath P. Pai, Simon Zhou, Wei Gao, Duxin Sun
    Biomaterials.2021; 275: 120910.     CrossRef
  • Breast cancer: Muscarinic receptors as new targets for tumor therapy
    Alejandro Español, Agustina Salem, Yamila Sanchez, María Elena Sales
    World Journal of Clinical Oncology.2021; 12(6): 404.     CrossRef
  • Direct Comparison of Analogous Amphiphilic Gradient and Block Polyoxazolines
    Lenka Loukotová, Pavel Švec, Ondřej Groborz, Tomáš Heizer, Hynek Beneš, Helena Raabová, Tereza Bělinová, Vít Herynek, Martin Hrubý
    Macromolecules.2021; 54(17): 8182.     CrossRef
  • Challenges towards Targeted Drug Delivery in Cancer Nanomedicines
    Muhammad Nadeem Hafeez, Christian Celia, Vilma Petrikaite
    Processes.2021; 9(9): 1527.     CrossRef
  • Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature
    Kah Min Yap, Mahendran Sekar, Shivkanya Fuloria, Yuan Seng Wu, Siew Hua Gan, Nur Najihah Izzati Mat Rani, Vetriselvan Subramaniyan, Chandrakant Kokare, Pei Teng Lum, M Yasmin Begum, Shankar Mani, Dhanalekshmi Unnikrishnan Meenakshi, Kathiresan V Sathasiva
    International Journal of Nanomedicine.2021; Volume 16: 7891.     CrossRef
  • Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
    Sung-Bae Kim, Jae Hong Seo, Jin-Hee Ahn, Tae-Yong Kim, Seok Yun Kang, Joohyuk Sohn, Yaewon Yang, Kyong Hwa Park, Yong Wha Moon, Seungtaek Lim, Myoung Joo Kang, Koung Eun Yoon, Hyun Ju Cho, Keun Seok Lee
    Therapeutic Advances in Medical Oncology.2021;[Epub]     CrossRef
  • Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy
    Chengyuan Dong, Quan Zhou, Jiajia Xiang, Fusheng Liu, Zhuxian Zhou, Youqing Shen
    Journal of Controlled Release.2020; 321: 529.     CrossRef
  • Clinical applications of nanomedicine in cancer therapy
    Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian, Fatemeh Atyabi
    Drug Discovery Today.2020; 25(1): 107.     CrossRef
  • Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis


    Pi-Ling Chou, Ya-Ping Huang, Meng-Hsuan Cheng, Kun-Ming Rau, Yi-Ping Fang
    International Journal of Nanomedicine.2020; Volume 15: 1731.     CrossRef
  • Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
    Adam S. Komorowski, Helen J. MacKay, Rossanna C. Pezo
    Cancer Medicine.2020; 9(14): 5035.     CrossRef
  • Nanotechnology for angiogenesis: opportunities and challenges
    Saeid Kargozar, Francesco Baino, Sepideh Hamzehlou, Michael R. Hamblin, Masoud Mozafari
    Chemical Society Reviews.2020; 49(14): 5008.     CrossRef
  • Furry nanoparticles: synthesis and characterization of nanoemulsion-mediated core crosslinked nanoparticles and their robust stability in vivo
    Rena Tanaka, Koichi Arai, Jun Matsuno, Miyo Soejima, Ji Ha Lee, Rintaro Takahashi, Kazuo Sakurai, Shota Fujii
    Polymer Chemistry.2020; 11(27): 4408.     CrossRef
  • Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval
    Duhyeong Hwang, Jacob D. Ramsey, Alexander V. Kabanov
    Advanced Drug Delivery Reviews.2020; 156: 80.     CrossRef
  • What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right
    Duxin Sun, Simon Zhou, Wei Gao
    ACS Nano.2020; 14(10): 12281.     CrossRef
  • Synthesis of PCL–PEG–PCL Triblock Copolymer via Organocatalytic Ring-Opening Polymerization and Its Application as an Injectable Hydrogel—An Interdisciplinary Learning Trial
    Kaiting Wu, Lin Yu, Jiandong Ding
    Journal of Chemical Education.2020; 97(11): 4158.     CrossRef
  • Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use


    Madhusmita Dhupal, Devasish Chowdhury
    International Journal of Nanomedicine.2020; Volume 15: 9125.     CrossRef
  • A Compressive Review about Taxol®: History and Future Challenges
    Julia Gallego-Jara, Gema Lozano-Terol, Rosa Alba Sola-Martínez, Manuel Cánovas-Díaz, Teresa de Diego Puente
    Molecules.2020; 25(24): 5986.     CrossRef
  • Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer
    Ruben AG van Eerden, Ron HJ Mathijssen, Stijn LW Koolen
    International Journal of Nanomedicine.2020; Volume 15: 8151.     CrossRef
  • Basic principles of drug delivery systems – the case of paclitaxel
    S. Ezrahi, A. Aserin, N. Garti
    Advances in Colloid and Interface Science.2019; 263: 95.     CrossRef
  • Biomolecules Turn Self-Assembling Amphiphilic Block Co-polymer Platforms Into Biomimetic Interfaces
    Saziye Yorulmaz Avsar, Myrto Kyropoulou, Stefano Di Leone, Cora-Ann Schoenenberger, Wolfgang P. Meier, Cornelia G. Palivan
    Frontiers in Chemistry.2019;[Epub]     CrossRef
  • Polyester Nanoparticle Encapsulation Mitigates Paclitaxel-Induced Peripheral Neuropathy
    R. Ganugula, M. Deng, M. Arora, H.-L. Pan, M. N. V. Ravi Kumar
    ACS Chemical Neuroscience.2019; 10(3): 1801.     CrossRef
  • PEGylation of Ginsenoside Rg3-Entrapped Bovine Serum Albumin Nanoparticles: Preparation, Characterization, and In Vitro Biological Studies
    Lijun Zhang, Junfeng Hui, Pei Ma, Yu Mi, Daidi Fan, Chenhui Zhu, Lei Chi, Yanan Dong
    Journal of Nanomaterials.2019; 2019: 1.     CrossRef
  • Prevention of paclitaxel-induced neuropathy by formulation approach
    Xiaowei Zang, Jong Bong Lee, Kiran Deshpande, Olga B. Garbuzenko, Tamara Minko, Leonid Kagan
    Journal of Controlled Release.2019; 303: 109.     CrossRef
  • Current status of nanomedicine in the chemotherapy of breast cancer
    A. I. Fraguas-Sánchez, C. Martín-Sabroso, A. Fernández-Carballido, A. I. Torres-Suárez
    Cancer Chemotherapy and Pharmacology.2019; 84(4): 689.     CrossRef
  • A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
    Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo
    The Oncologist.2019; 24(6): 751.     CrossRef
  • Advances in thermosensitive polymer-grafted platforms for biomedical applications
    Phung Ngan Le, Chan Khon Huynh, Ngoc Quyen Tran
    Materials Science and Engineering: C.2018; 92: 1016.     CrossRef
  • Supramolecular polymeric chemotherapy based on cucurbit[7]uril-PEG copolymer
    Hao Chen, Yueyue Chen, Han Wu, Jiang-Fei Xu, Zhiwei Sun, Xi Zhang
    Biomaterials.2018; 178: 697.     CrossRef
  • pH/NIR-Responsive Polypyrrole-Functionalized Fibrous Localized Drug-Delivery Platform for Synergistic Cancer Therapy
    Arjun Prasad Tiwari, Tae In Hwang, Jung-Mi Oh, Bikendra Maharjan, Sungkun Chun, Beom Su Kim, Mahesh Kumar Joshi, Chan Hee Park, Cheol Sang Kim
    ACS Applied Materials & Interfaces.2018; 10(24): 20256.     CrossRef
  • The Blood Clearance Kinetics and Pathway of Polymeric Micelles in Cancer Drug Delivery
    Xuanrong Sun, Guowei Wang, Hao Zhang, Shiqi Hu, Xin Liu, Jianbin Tang, Youqing Shen
    ACS Nano.2018; 12(6): 6179.     CrossRef
  • Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles
    Feng Li, Huixia Zhang, Miao He, Jinhui Liao, Nianhang Chen, Yan Li, Simon Zhou, Maria Palmisano, Alex Yu, Manjunath P. Pai, Hebao Yuan, Duxin Sun
    Molecular Pharmaceutics.2018; 15(10): 4505.     CrossRef
  • Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery
    Longfa Kou, Rui Sun, Yangzom D. Bhutia, Qing Yao, Ruijie Chen
    Expert Opinion on Drug Delivery.2018; 15(9): 869.     CrossRef
  • The battle of “nano” paclitaxel
    Alexandros Marios Sofias, Michael Dunne, Gert Storm, Christine Allen
    Advanced Drug Delivery Reviews.2017;[Epub]     CrossRef
  • Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic
    Loujin Houdaihed, James C. Evans, Christine Allen
    Molecular Pharmaceutics.2017; 14(8): 2503.     CrossRef
  • PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
    Philip Grossen, Dominik Witzigmann, Sandro Sieber, Jörg Huwyler
    Journal of Controlled Release.2017; 260: 46.     CrossRef
  • Effect of Thermoresponsive Poly(L-lactic acid)–poly(ethylene glycol) Gel Injection on Left Ventricular Remodeling in a Rat Myocardial Infarction Model
    Shota Somekawa, Atsushi Mahara, Kazunari Masutani, Yoshiharu Kimura, Hiroshi Urakawa, Tetsuji Yamaoka
    Tissue Engineering and Regenerative Medicine.2017; 14(5): 507.     CrossRef
  • A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer
    Xin-shuai Wang, De-jiu Kong, Tzu-yin Lin, Xiao-cen Li, Yoshihiro Izumiya, Xue-zhen Ding, Li Zhang, Xiao-chen Hu, Jun-qiang Yang, She-gan Gao, Kit S Lam, Yuan-pei Li
    Acta Pharmacologica Sinica.2017; 38(6): 931.     CrossRef
  • 17,485 View
  • 637 Download
  • 72 Web of Science
  • 67 Crossref
Close layer
Meta-Analysis
Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
Yo-Han Cho, So Young Yoon, Soo-Nyung Kim
Cancer Res Treat. 2017;49(1):255-262.   Published online May 18, 2016
DOI: https://doi.org/10.4143/crt.2015.452
AbstractAbstract PDFPubReaderePub
Purpose
A meta-analysis was conducted to examine the question of whether combination regimens are more effective than monotherapy as a second-line chemotherapy in advanced gastric cancer.
Materials and Methods
The MEDLINE and the EMBASE databases and the Cochrane Central Register for Controlled Trials were searched using appropriate keywords. Only randomized controlled trials were eligible.
Results
Taxane-based study is rare; thus, four irinotecan-based studies were finally included in the meta-analysis. Out of 661 patients, 331 patients were assigned to combination therapy and 330 to monotherapy. Cisplatin or fluoropyrimidine (S-1 or 5-fluorouracil) was used as a combination partner to irinotecan. The pooled hazard ratio (HR) for overall survival (OS) and for progression-free survival (PFS) was 0.938 (95% confidence interval [CI], 0.796 to 1.104; p=0.442) and 0.815 (95% CI, 0.693 to 0.958; p=0.013). In subgroup analysis according to previous exposure to a partner agent, the PFS benefit of combination was observed only in the partially exposed group (HR, 0.784; 95% CI, 0.628 to 0.980; p=0.032).
Conclusion
Second-line irinotecan-based combination was not associated with increased OS, but with PFS benefit, which seemed particularly significant for patients receiving combination with a new agent.

Citations

Citations to this article as recorded by  
  • Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis
    Paul O. Odeniran, Paradise Madlala, Nompumelelo P. Mkhwanazi, Mahmoud E. S. Soliman
    Cancers.2024; 16(22): 3802.     CrossRef
  • Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
    N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi
    Medical Council.2019; (10): 100.     CrossRef
  • Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
    Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, Angelica Petrillo, Rosa Berenato, Maria Maddalena Laterza, Filippo Pietrantonio, Federica Morano, Maria Antista, Sara Lonardi, Lorenzo Fornaro, Stefano Tamberi, Elisa Giommoni, Alberto Zaniboni, Lorenza
    Targeted Oncology.2018; 13(2): 227.     CrossRef
  • Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver
    Iera Hernandez-Unzueta, Aitor Benedicto, Elvira Olaso, Eduardo Sanz, Cristina Viera, Beatriz Arteta, Joana Márquez
    Oncology Letters.2017; 13(6): 4002.     CrossRef
  • 11,230 View
  • 216 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Case Reports
Pleural Metastasis as Initial Presentation of Occult Gastric Cardia Cancer: A Possible Role of PET-CT in Diagnosis
So Young Yoon, Jeong Hwan Kim, Wan Seop Kim, Hyun Woo Chung, Mark Hong Lee, Sung Yong Kim, Yo Han Cho
Cancer Res Treat. 2014;46(4):415-418.   Published online July 18, 2014
DOI: https://doi.org/10.4143/crt.2013.068
AbstractAbstract PDFPubReaderePub
We report on a case of malignant pleural effusion as initial metastatic presentation of occult gastric cardia cancer in a young woman. To the best of our knowledge, this is the first report of gastric adenocarcinoma metastasized to pleura as an initial presentation. Location of cardia and signet ring cell histology may contribute to the manifestation. Utilization of PET/CT was helpful for proper diagnosis. For patients with such distinct clinical presentations, it would be appropriate to consider gastric cancer as one of the possible primary sites.
  • 11,233 View
  • 58 Download
Close layer
Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT
So Young Yoon, Sung-Yong Kim, Yo-Han Cho, Hyun Woo Chung, Young So, Hong M Lee
Cancer Res Treat. 2009;41(2):100-103.   Published online June 30, 2009
DOI: https://doi.org/10.4143/crt.2009.41.2.100
AbstractAbstract PDFPubReaderePub

We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib (1-6). However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.

Citations

Citations to this article as recorded by  
  • Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
    Yassine Lalami, Camillo Garcia, Patrick Flamen, Lieveke Ameye, Marianne Paesmans, Ahmad Awada
    Head & Neck.2016; 38(3): 347.     CrossRef
  • A Case of Long-Term Complete Remission of Advanced Gastric Adenocarcinoma with Liver Metastasis
    Ch'angbum Rim, Jung-Ae Lee, Soojung Gong, Dong Wook Kang, Heebum Yang, Hyun Young Han, Nae Yu Kim
    Journal of Gastric Cancer.2016; 16(2): 115.     CrossRef
  • PRELIMINARY EVALUATION OF SERIAL 18FDG‐PET/CT TO ASSESS RESPONSE TO TOCERANIB PHOSPHATE THERAPY IN CANINE CANCER
    Amy K. LeBlanc, Ashley N. Miller, Gina D. Galyon, Tamberlyn D. Moyers, Misty J. Long, Alan C. Stuckey, Jonathan S. Wall, Federica Morandi
    Veterinary Radiology & Ultrasound.2012; 53(3): 348.     CrossRef
  • Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku, Hyun C. Chung, Jen-Shi Chen, Toshihiko Doi, Yan Sun, Lin Shen, Shukui Qin, Wai-Tong Ng, Jennifer M. Tursi, Maria J. Lechuga, Dongrui Ray Lu, Ana Ruiz-Garcia, Alberto Sobrero
    Investigational New Drugs.2011; 29(6): 1449.     CrossRef
  • 8,406 View
  • 57 Download
  • 4 Crossref
Close layer
Original Articles
Microsatellite Alterations in Serum DNA of Lung Cancer Patients
Sang Cheul Oh, Young Do Yoo, So Young Yoon, Seok Jin Kim, Jae Hong Seo, Kwang Taek Kim, Sang Won Shin, Yo Han Kim, Yeul Hong Kim, Jun Suk Kim
Cancer Res Treat. 2003;35(4):289-293.   Published online August 31, 2003
DOI: https://doi.org/10.4143/crt.2003.35.4.289
AbstractAbstract PDF
No abstract available.
  • 4,289 View
  • 19 Download
Close layer
Pilot Study of Heptaplatin, UFT-E and Leucovorin in Advanced Gastric Carcinoma
Sang Cheul Oh, So Young Yoon, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Si Young Kim, Hwi Joong Yoon, Kyung Sam Cho, Jun Suk Kim
Cancer Res Treat. 2003;35(2):117-122.   Published online April 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.2.117
AbstractAbstract PDF
PURPOSE
Heptaplatin (SKI-2053R, Sunpla ), a new platinum analogue which has a better toxicity profile than cisplatin, has been used with 5-fluorouracil (5-FU) continuous infusion for the treatment of advanced gastric carcinoma. However, continuous 5-FU infusion had a inconvenience to administration. The aim of this study was to evaluate the efficacy and toxicity of heptaplatin, UFT-E and leucovorin combination chemotherapy in advanced gastric cancer.
MATERIALS AND METHODS
A total of 22 patients was enrolled in this study at Kyung Hee University and Korea University from September 1999 to May 2001. Heptaplatin 400 mg/m2 was given as intravenous infusion for 1 hour at day 1. Oral UFT-E 360 mg/m2 and leucovorin 45 mg/day were administered for 21 consecutive days followed by a 7-day drug free interval. This schedule was repeated every 4 weeks. RESULTS: The 22 enrolled patients received 81 courses of chemotherapy and the median number of course per patient was three with a range of one to six. Five of 21 patients achieved partial responses (23.8%; 95% confidence interval, 5.6% to 42%) without complete response. Out of the 5 responding patients, three had unresectable perigastric lymph-nodes, one patient had a ovarian metastasis, and one patient had a peritoneal metastasis respectively. Main toxicities were neutropenia and nausea/vomiting. Grade 3 and 4 neutropenia were observed in 4 patients (18%) and grade 3 nausea/vomiting were observed in 5 patients (22.7%). The median time to progression was 4 months (range, 0.5 to 13 months), and median survival duration was 7.5 months (range, 2.0 to 14 months). Median response duration was 5.0 months (range, 1.5 to 10 months). CONCLUSION: A combination chemotherapy of heptaplatin, UFT-E and leucovorin has a comparable efficacy with those of previously reported heptaplatin and intravenous regimen of 5-FU and controllable toxicity in advanced gastric carcinoma. Further study with large patient population is warranted to determine the usefulness of this regimen.

Citations

Citations to this article as recorded by  
  • Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters
    Xi Hu, Fangyuan Li, Nabila Noor, Daishun Ling
    Science Bulletin.2017; 62(8): 589.     CrossRef
  • The status of platinum anticancer drugs in the clinic and in clinical trials
    Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
    Dalton Transactions.2010; 39(35): 8113.     CrossRef
  • A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer
    Won Sup Lee, Gyeong-Won Lee, Hwal Woong Kim, Ok-Jae Lee, Young-Joon Lee, Gyung Hyuck Ko, Jong-Seok Lee, Joung Soon Jang, Woo Song Ha
    Cancer Research and Treatment.2005; 37(4): 208.     CrossRef
  • Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study
    Myung-Ju Ahn, Ho-Suck Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon
    Cancer Research and Treatment.2004; 36(3): 182.     CrossRef
  • 4,462 View
  • 23 Download
  • 4 Crossref
Close layer
Oral Etoposide, Ifosfamide and Cisplatin in the Treatment of Extensive Disease Small Cell Lung Cancer
Seok Jin Kim, Hwa Jung Sung, Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Kwang Taek Kim, Young Ho Choi, Jun Suk Kim
Cancer Res Treat. 2002;34(6):421-425.   Published online December 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.6.421
AbstractAbstract PDF
PURPOSE
The combination of cisplatin and etoposide has been a common first line regimen for the treatment of small cell lung cancer (SCLC). The schedule dependence, and equal efficacy, of the oral and intravenous dosing of etoposide has led to prolonged administration of oral etoposide, which is known to produce an encouraging response in SCLC. To improve the efficacy of the cisplatin/etoposide combination, we administered oral etoposide, with added ifosfamide, which had significant single agent activity against SCLC. We conducted this study to evaluate the efficacy and toxicity of the cisplatin, ifosfamide and oral etoposide (PIE) combination in patients with extensive small cell lung cancer.
MATERIALS AND METHODS
Twenty-five patients with histologically confirmed extensive small cell lung cancer were enrolled into this study between January 2000 and May 2002. They were treated with, cisplatin at 20 mg/ m2/day, ifosfamide 1.5 g/m2/day, with mesna (all given intravenously on Days 1~3), and oral etoposide 50 mg/m2 on days 4~17. This cycle was repeated every 4 weeks for up to 6 cycles. We evaluated the corresponding disease responses and toxicities.
RESULTS
The patients' characteristics were as follows: median age 65 years (32~75), 19 males and 6 females. The performance stati were ECOG 0 in 3 patients, ECOG 1 in 12 and ECOG 2 in 10. Sixteen patients had a partial response, 2 had a stable disease and 4 had a progressive disease. Thus, the overall objective response rate was 72.7% (95% CI: 49.6~88.4%), with a median response duration of 7 months (95% CI: 3.5~10.5 months). Myelosuppression was the major observed toxicity. Grades III and IV neutropenia were observed in 42 (46.1%) of the 91 cycles. Significant non-hematological toxicities (>or=Grade III) were uncommon, with the exception of nausea and vomiting.
CONCLUSION
The response rate to the combination of cisplatin, ifosfamide and oral etoposide was similar to that of other combination chemotherapy studies in patients with extensive disease small cell lung cancer. The toxicity of the regimen was considered acceptable.
  • 4,577 View
  • 26 Download
Close layer
Pirarubicin, UFT, Leucovorin Chemotherapy in Non-embolizable and Transcatheter Arterial Chemoembolization-Failed Hepatocellular Carcinoma Patients; A Phase II Clinical Study
Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Jong Eun Yeon, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Kwan Soo Byun, Jun Suk Kim, Chang Hong Lee
Cancer Res Treat. 2002;34(4):280-283.   Published online August 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.4.280
AbstractAbstract PDF
Hepatocellular carcinomas are one of the most common malignancies in the world. However, no effective therapeutic modality has been proven to prolong the survival of patients in an inoperable stage. The purpose of this study was to determine the response rate and the toxicities of a combination of pirarubicin, UFT and leucovorin in patients with non-embolizable hepatocellular carcinomas, or who had progressed during their transcatheter arterial chemoembolization treatment.
MATERIALS AND METHODS
Of 23 patients with a hepatocellular carcinoma, 11 had progressed during a transcatheter arterial chemoembolization, with the other 12 being transcatheter arterial chemoembolization-naive. All the patients were treated with pirarubicin (70 mg/m2 i.v., day 1), UFT (350 mg/m2 P.O., day 1~21), and leucovorin (25 mg/m2 P.O., day 1~21).
RESULTS
Twenty patients were able to be evaluated, with a partial response being achieved in four, giving an overall response rate of 20% (95% confidence interval, 7~44%). The median overall survival time was 6 months, and the median survival time of the transcatheter arterial chemoembolization-naive patients was significantly longer than that of those treated by transcatheter arterial chemoembolization (p=0.012). The most significant dose-limiting toxicity was leucopenia and thrombocytopenia.
CONCLUSION
The combination of pirarubicin, UFT and leucovorin therapies showed marginal antitumor activity and significant toxicity in patients with non-embolizable or failed transcatheter arterial chemoembolization hepatocellular carcinomas.
  • 4,276 View
  • 17 Download
Close layer
Phase II Trial of Gemcitabine, UFT-E, Leucovorin Combination Chemotherapy in Advanced Pancreatic Adenocarcinoma
So Young Yoon, Kyong Hwa Park, Sang Chul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Jae Seon Kim, Chang Duck Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim
Cancer Res Treat. 2002;34(2):111-116.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.111
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and toxicity of a Gemcitabine, UFT-E, Leucovorin combination chemotherapy in the treatment of advanced pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients <=70 years, with no prior chemotherapy and with bidimensionally measurable advanced pancreatic adenocarcinoma, ECOG performance status <=2, and adequate bone marrow, kidney, and liver function were eligible for this trial. Eligibility criteria for clinical benefit assessment were pain with at least a daily analgesic consumption of two nonsteroidal anti-inflammatory drugs or a Karnofsky performance status between 50 and 70. Treatment consisted of 1,000 mg/m2 of Gemcitabine on days 1, 8 and 15, repeated every 4 weeks, with UFT-E administered orally 500 mg-700 mg by body surface area (BSA). Leucovorin was administered 45 mg/day orally. Dosages of UFT-E and Leucovorin were divided and administered three times per day from day 1 to day 21. After 7 days of rest, UFT-E and Leucovorin were administered repeatedly.
RESULTS
Twenty-three patients were enrolled between April 1999 to April 2000. Eighty two cycles (median, four cycles) were delivered to all patients. The objective response rate was 15.8% in 19 assessable patients and 13.0% in the intent-to-treat population. Twelve patients (57.9%) displayed stable disease. Grade 3 or 4 neutropenia occurred in 30.4% of patients, nausea/vomiting in 8.3%, diarrhea in 4.3%, and mucositis in 4.3%. The median time to progression was 8 months. The median survival was 8 months in the assessable population and 6 months in the intent-to-treat population Clinical benefit was achieved in 11 (57.9%) of 19 assessable patients.
CONCLUSION
Gemcitabine, UFT-E, Leucovorin combination chemotherapy is a well-tolerated and safe regimen in cases of advanced pancreatic adenocarcinoma. Although the response rate is low, it shows a survival benefit and clinical benefit and deserves further evaluation in a phase III trial.

Citations

Citations to this article as recorded by  
  • Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim
    Cancer Chemotherapy and Pharmacology.2009; 64(2): 317.     CrossRef
  • 4,547 View
  • 18 Download
  • 1 Crossref
Close layer
Concurrent Chemoradiation Therapy with Cisplatin and Oral Etoposide for Locally Advanced Non-small Cell Lung Cancer
Chang Won Paek, So Young Yoon, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jae Jung Shim, Kyung Ho Kang, Jun Suk Kim, Chul Yong Kim, Myung Sun Choi, Young Ho Choi, Kwang Tak Kim
J Korean Cancer Assoc. 2000;32(4):682-689.
AbstractAbstract PDF
PURPOSE
Prognosis of locally advanced inoperable non-small cell lung cancer (NSCLC) treated with radiation therapy alone has been disappointing. In recent years, concurrent chemoradiation therapy has potential of improving both local and metastatic disease-free survival. This phase II study was undertaken to determine the feasibility, toxicity, response rate, local control rate, and survival duration of locally advanced NSCL patients treated with concurrent chemoradiation using cisplatin and oral etoposide. MATERIAL AND METHODS: Forty-seven patients were enrolled and forty-one patients were evaluable. Chemotheray consisted of cisplatin 50 mg/m2/IV on days 1 and 8 and oral etoposide 100 mg/day on days 1 to 5 and 8 to 12 which was repeated, every 4 weeks for two cycles during radiation therapy. Radiation therapy was administered to a total dose of 6300 cGY.
RESULTS
Among 41 evaluable patients, six patients achieved complete response, and twenty had partial response, for an overall response rate of 63.4% (95% confidence interval; 48.4% to 75.4%). Stable disease was reported in 10 patients (24.4%) and another 5 (12.2%) showed disease pro gression. Overall survival rate was 76% at 1 year, 34% at 2 years. Median survival duration was 17 months (range; 3 to 41 ). Eighty-three percents of patients had radiation pneumonitis but only one patients needed medical treatment.
CONCLUSION
Concurrent chemoradiation therapy with cisplatin and oral etoposide at this level is a well tolerated and feasible.
  • 3,235 View
  • 20 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP